Table 5 Pathway enrichment analysis of potential target genes in HN1957 for miRNAs responding to therapy in HNSCC patients (FDR < 0.05)
Pathway | Number of Proteins in Pathway | Proteins from Gene List | P-value | FDR | Genes |
|---|---|---|---|---|---|
Pathways in cancer (K) | 327 | 7 | 0.0004 | 1.40E-02 | E2F1,PTEN,AKT2,MSH6,HSP90AA1,JUN,VEGFA |
Direct p53 effectors (N) | 133 | 5 | 0.0002 | 1.40E-02 | E2F1,PTEN,SP1,JUN,SMARCA4 |
Hepatitis B (K) | 146 | 5 | 0.0004 | 1.38E-02 | E2F1,PTEN,AKT2,JUN,YWHAQ |
Nonsense-mediated decay (R) | 106 | 5 | 0.0001 | 1.55E-02 | RPL30,UPF1,SMG7,RNPS1,RPL18A |
RNA transport (K) | 164 | 5 | 0.0006 | 1.50E-02 | EEF1A1,UPF1,RNPS1,EIF4G2,NUP205 |
E2F transcription factor network (N) | 68 | 4 | 0.0002 | 1.44E-02 | E2F1,KAT2B,SP1,RRM2 |
Estrogen signaling pathway (K) | 100 | 4 | 0.0009 | 1.69E-02 | AKT2,HSP90AA1,SP1,JUN |
Glucocorticoid receptor regulatory network (N) | 77 | 4 | 0.0003 | 1.34E-02 | SMARCD1,HSP90AA1,JUN,SMARCA4 |
HIF-1-alpha transcription factor network (N) | 66 | 4 | 0.0002 | 2.03E-02 | NPM1,SP1,JUN,VEGFA |
Huntington disease (P) | 121 | 4 | 0.0017 | 2.79E-02 | GAPDH,AKT2,AP2A2,JUN |
Processing of capped intron-containing pre-mRNA (R) | 138 | 4 | 0.0028 | 3.33E-02 | DDX23,PCBP1,RNPS1,NUP205 |
Prostate cancer (K) | 89 | 4 | 0.0006 | 1.56E-02 | E2F1,PTEN,AKT2,HSP90AA1 |
Regulation of androgen receptor activity (N) | 49 | 4 | 0.0001 | 1.70E-02 | KAT7,HSP90AA1,KAT2B,JUN |
Regulation of telomerase (N) | 68 | 4 | 0.0002 | 1.44E-02 | E2F1,HSP90AA1,SP1,JUN |